Q-omics provides the consensus-scored TSPAN15 profile across patient tissues and cancer cell-line models. TSPAN15 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TSPAN15 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, TSPAN15 protein abundance shows 29,908 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KICH, and GBM as cancer lineages where TSPAN15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPAN15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPAN15 survival associations across molecular data types. TSPAN15 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPAN15 RNA expression–survival associations across cancer types. High TSPAN15 expression shows unfavorable associations in ACC, KIRP, LIHC and PAAD, but favorable associations in MESO and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TSPAN15 RNA expression.
This table summarizes TSPAN15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for TSPAN15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPAN15 shows lower tumor expression in KICH and LUSC and higher tumor expression in HNSC, LIHC, STAD and BRCA. The KICH box plot shows higher TSPAN15 RNA expression in normal versus tumor tissue (log2 FC = −2.597, t-test p < 0.001).
This table shows molecular features associated with TSPAN15 in patient tissues and cancer cell lines. In patient samples, TSPAN15 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TSPAN15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUAD.
